Literature DB >> 16956650

Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.

Daniel R Scoles1, James Pavelka, Ilana Cass, Hang Tran, Rae L Baldwin, Klara Armstrong, Beth Y Karlan.   

Abstract

OBJECTIVE: Only a small number of comprehensively characterized immortalized ovarian cancer cell lines are available for laboratory studies on ovarian cancer. We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882.
METHODS: We characterized CSOC 882 by karyotyping, growth modeling, immunohistochemical staining, immunoblotting, drug sensitivity testing, and xenografting in nude mice.
RESULTS: CSOC 882 possessed an abnormal tetraploid karyotype including loss of one copy of chromosomes 2, 17, 19, and 21, and deletion of 8p21. Growth of CSOC 882 was best modeled using the logistic growth equation revealing an average doubling time of 31 h. CSOC 882 cells expressed vimentin, cytokeratin, p53, BRCA1, EGF receptor, HER2, androgen receptor, estrogen receptor alpha, and progesterone receptor, while no evidence of estrogen receptor beta or factor VIII was observed. Some but not all CSOC 882 cells were positive for CA125 reflecting the primary tumor, which had patchy CA125 staining. Drug sensitivity assays demonstrated that CSOC 882 was more sensitive to cisplatin and carboplatin than SKOV3 and HCC1937 while CSOC 882 and SKOV3 were both sensitive to paclitaxel unlike HCC1937. CSOC 882 xenografts retained the original characteristics of vimentin, cytokeratin, and factor VIII labeling.
CONCLUSIONS: CSOC 882 is an immortalized cell line that has survived more than 130 passages in culture and retained molecular features of the primary tumor from which it was derived. Compared to the most common ovarian carcinoma cell lines, CSOC 882 is a unique resource for genetic and cellular research on ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956650     DOI: 10.1016/j.ygyno.2006.07.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Establishment of a New Ovarian Cancer Cell Line CA5171.

Authors:  Ying-Cheng Chiang; Wen-Fang Cheng; Ming-Cheng Chang; Tzu-Pin Lu; Kuan-Ting Kuo; Hsiu-Ping Lin; Chang-Yao Hsieh; Chi-An Chen
Journal:  Reprod Sci       Date:  2014-11-12       Impact factor: 3.060

Review 2.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

3.  Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line.

Authors:  HanByoul Cho; Eun Suk Kang; Soon Won Hong; Youn Jin Oh; Sun Mi Choi; Sang Wun Kim; Sung Hoon Kim; Young Tae Kim; Kyoung Sun Lee; Yang Kyu Choi; Jae-Hoon Kim
Journal:  Mol Cell Biochem       Date:  2008-08-06       Impact factor: 3.396

4.  Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.

Authors:  Ayala Tamir; Ushma Jag; Sreeja Sarojini; Craig Schindewolf; Takemi Tanaka; Rajendra Gharbaran; Hiren Patel; Anil Sood; Wei Hu; Ruzeen Patwa; Patrick Blake; Polina Chirina; Jin Oh Jeong; Heejin Lim; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Ovarian Res       Date:  2014-12-05       Impact factor: 4.234

5.  Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer.

Authors:  Thore Hillig; Jørgen Thode; Marie F Breinholt; Maria-Benedicte Franzmann; Carsten Pedersen; Flemming Lund; Henrik Mygind; György Sölétormos; Martin Rudnicki
Journal:  APMIS       Date:  2012-06-26       Impact factor: 3.205

6.  Characterization of three new serous epithelial ovarian cancer cell lines.

Authors:  Véronique Ouellet; Magdalena Zietarska; Lise Portelance; Julie Lafontaine; Jason Madore; Marie-Line Puiffe; Suzanna L Arcand; Zhen Shen; Josée Hébert; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-05-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.